{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:29:23Z","timestamp":1761744563957},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1097\/md.0000000000007568","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T19:38:09Z","timestamp":1501011489000},"page":"e7568","source":"Crossref","is-referenced-by-count":27,"title":["Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection"],"prefix":"10.1097","volume":"96","author":[{"given":"Keliang","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rijin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiexiu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongzhen","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-35-20210309","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/TP.0b013e3181f92548","article-title":"Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand","volume":"90","author":"Scott","year":"2010","journal-title":"Transplantation"},{"key":"R2-35-20210309","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.transproceed.2009.01.074","article-title":"Impact of hepatitis B and C virus infections on kidney transplantation: a single center experience","volume":"41","author":"Santos","year":"2009","journal-title":"Transplant Proc"},{"key":"R3-35-20210309","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1097\/01.tp.0000238898.14393.c9","article-title":"Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant","volume":"82","author":"Kamar","year":"2006","journal-title":"Transplantation"},{"key":"R4-35-20210309","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/jvh.12276","article-title":"Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies","volume":"21","author":"Fabrizi","year":"2014","journal-title":"J Viral Hepat"},{"key":"R5-35-20210309","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature04083","article-title":"Hepatitis C and liver transplantation","volume":"436","author":"Brown","year":"2005","journal-title":"Nature"},{"key":"R6-35-20210309","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1111\/ajt.12835","article-title":"Hepatitis C virus infection and kidney transplantation in 2014: what's new?","volume":"14","author":"Baid-Agrawal","year":"2014","journal-title":"Am J Transplant"},{"key":"R7-35-20210309","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/ki.2013.264","article-title":"Hepatitis C treatment in patients with kidney disease","volume":"84","author":"Fabrizi","year":"2013","journal-title":"Kidney Int"},{"key":"R8-35-20210309","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/j.1365-2036.2006.03151.x","article-title":"Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients","volume":"24","author":"Fabrizi","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-35-20210309","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1111\/j.1365-2893.2010.01405.x","article-title":"Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials","volume":"18","author":"Fabrizi","year":"2011","journal-title":"J Viral Hepat"},{"key":"R10-35-20210309","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2008.05.002","article-title":"Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin","volume":"49","author":"Berenguer","year":"2008","journal-title":"J Hepatol"},{"key":"R11-35-20210309","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.kint.2016.09.046","article-title":"Gitelman syndrome: consensus and guidance from a kidney disease: improving global outcomes (KDIGO) controversies conference","volume":"91","author":"Blanchard","year":"2017","journal-title":"Kidney Int"},{"key":"R12-35-20210309","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0272-6386(03)00422-0","article-title":"Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology","volume":"42","author":"Kamar","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R13-35-20210309","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jcv.2003.10.001","article-title":"Amantadine therapy in renal transplant patients with hepatitis C virus infection","volume":"30","author":"Kamar","year":"2004","journal-title":"J Clin Virol"},{"key":"R14-35-20210309","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcv.2007.02.006","article-title":"Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone","volume":"39","author":"Calanca","year":"2007","journal-title":"J Clin Virol"},{"key":"R15-35-20210309","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jhep.2014.04.037","article-title":"A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy","volume":"61","author":"Burton","year":"2014","journal-title":"J Hepatol"},{"key":"R16-35-20210309","first-page":"388","article-title":"Protease inhibitor therapy post-liver transplantation in the treatment of hepatitis C virus infection","volume":"9","author":"Nair","year":"2013","journal-title":"Gastroenterol Hepatol (N Y"},{"key":"R17-35-20210309","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1665-2681(19)31252-9","article-title":"Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience","volume":"13","author":"Faisal","year":"2014","journal-title":"Ann Hepatol"},{"key":"R18-35-20210309","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/liv.12406","article-title":"Management of HCV transplant patients with triple therapy","volume":"34","author":"Coilly","year":"2014","journal-title":"Liver Int"},{"key":"R19-35-20210309","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"R20-35-20210309","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"R21-35-20210309","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"R22-35-20210309","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"R23-35-20210309","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"R24-35-20210309","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/S0140-6736(15)60159-3","article-title":"Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial","volume":"385","author":"Hezode","year":"2015","journal-title":"Lancet"},{"key":"R25-35-20210309","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"R26-35-20210309","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/ajg.2014.66","article-title":"The rapid evolution of treatment strategies for hepatitis C","volume":"109","author":"Muir","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"R27-35-20210309","doi-asserted-by":"crossref","first-page":"1821.e6","DOI":"10.1016\/j.cgh.2016.07.001","article-title":"Safety and effectiveness of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection and cirrhosis","volume":"14","author":"Maan","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R28-35-20210309","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jebm.12141","article-title":"The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review","volume":"8","author":"Zeng","year":"2015","journal-title":"J Evid Based Med"},{"key":"R29-35-20210309","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/tri.12799","article-title":"DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting","volume":"29","author":"Beinhardt","year":"2016","journal-title":"Transpl Int"},{"key":"R30-35-20210309","doi-asserted-by":"crossref","first-page":"e0158431","DOI":"10.1371\/journal.pone.0158431","article-title":"Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C virus infection","volume":"11","author":"Lin","year":"2016","journal-title":"PLoS One"},{"key":"R31-35-20210309","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/ajt.13518","article-title":"Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation","volume":"16","author":"Kamar","year":"2016","journal-title":"Am J Transplant"},{"key":"R32-35-20210309","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1097\/TP.0000000000001618","article-title":"Safety and efficacy of treatment of Hepatitis C in kidney transplant recipients with directly acting antiviral agents","volume":"101","author":"Lubetzky","year":"2017","journal-title":"Transplantation"},{"key":"R33-35-20210309","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/ajt.13620","article-title":"Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents","volume":"16","author":"Sawinski","year":"2016","journal-title":"Am J Transplant"},{"key":"R34-35-20210309","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"R35-35-20210309","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jhep.2015.09.002","article-title":"Pros and cons: usage of organs from donors infected with hepatitis C virus\u2014revision in the direct-acting antiviral era","volume":"64","author":"Coilly","year":"2016","journal-title":"J Hepatol"},{"key":"R36-35-20210309","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","article-title":"An interferon-free antiviral regimen for HCV after liver transplantation","volume":"371","author":"Kwo","year":"2014","journal-title":"N Engl J Med"},{"key":"R37-35-20210309","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1111\/liv.12856","article-title":"Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients","volume":"35","author":"Saab","year":"2015","journal-title":"Liver Int"},{"key":"R38-35-20210309","doi-asserted-by":"crossref","first-page":"e000066","DOI":"10.1136\/bmjgast-2015-000066","article-title":"Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis","volume":"3","author":"Nguyen","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"key":"R39-35-20210309","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/j.dld.2014.10.005","article-title":"Extrahepatic manifestations of chronic hepatitis C virus infection","volume":"46","author":"Cacoub","year":"2014","journal-title":"Dig Liver Dis"},{"key":"R40-35-20210309","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/tid.12606","article-title":"The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C","volume":"18","author":"Raschzok","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"R41-35-20210309","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1002\/hep.27770","article-title":"Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant","volume":"61","author":"Pungpapong","year":"2015","journal-title":"Hepatology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000007568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:55:24Z","timestamp":1620960924000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201707280-00035"}},"subtitle":["A PRISMA-compliant study"],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":41,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000007568","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}